iShares Micro-Cap

Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

Wall Street analysts estimate that INSY stock could decrease ~3% over the next 12 months. That show a 12-month target price of $9.60.

Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.

Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

ZomaJet is Antares Pharma’s needle-free autoinjector, which is designed to deliver human growth hormone (or HGH) treatment to children with growth retardation.

Short interest in Flotek Industries (FTK) as a percentage of its float was 20.3% on October 16, 2017, compared to 22.8% on June 30, 2017.

In 3Q17, analysts expect Flotek Industries (FTK) to report adjusted earnings per share of $0.02. Wall Street expects FTK’s revenues to rise 1% over 2Q17 to $86.2 million.

Since 2Q17 earnings were announced on July 27, Basic Energy Services’ implied volatility (or IV) has risen from 62% to the current level.

Basic Energy Services’ (BAS) management expects steady well completion activity until mid-2018, which should benefit the company.

On August 10, 2017, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.” None of the analysts rated Flotek as a “hold” or “sell.”

Flotek Industries’ (FTK) cash from operating activities (or CFO) remained negative in 2Q17, continuing with a negative cash flow trend in 1Q17.

From 2Q16 to 2Q17, Flotek Industries’ (FTK) EBITDA margin (or EBITDA as a percentage of revenues) improved to 2.3% from 0.7%.

Flotek’s (FTK) CFO (cash from operating activities) was negative in 1Q17, after being positive for three quarters. FTK’s CFO was -$2.5 million in 1Q17.

From 1Q16 to 1Q17, Flotek’s EBITDA margin shrank to 3.3% from 4.1%. FTK’s EBITDA margin has been 1.7%, on average, for the past five quarters.

Short interest in Basic Energy Services (BAS) as a percentage of its float is 4.4% as of May 8 compared to 4.6% as of March 31, 2017.

On October 25, 2016, Basic Energy Services (BAS) filed for bankruptcy after a persistently weak performance in an energy market that was gripped by pricing weakness.

Basic Energy Services’ (BAS) management expects increased rig utilization and better pricing to result in a higher operating margin in 1Q17.

On May 3, 2017, after Flotek Industries’ 1Q17 earnings were released, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.”

Among our group of OFS companies, analysts expect Halliburton (HAL) to see the highest rise in adjusted EPS in 1Q17.

In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flows trended over the past few quarters.

In the past few years, some major US upstream and integrated companies reduced their capex following the sharp fall in crude oil prices.

From April 1 to September 30 of fiscal 2017, Tidewater’s (TDW) revenues fell 46% compared to the same period in fiscal 2016.

On January 13, all the analysts tracking Flotek Industries rated it a “buy” or some equivalent.

On January 13, 2017, Flotek Industries (FTK) had an implied volatility of 81%.

In the past couple of years, some of the major US upstream and integrated companies have reduced capital expenditure as a result of crude oil’s sharp decline.

In 4Q16, analysts expect Flotek Industries (FTK) to post an adjusted loss per share of ~$0.04.

Tidewater’s net loss fell to $267.5 million in the first six months of 2017—compared to an ~$59 million net loss in the first six months of 2016.

Among the Wall Street analysts tracking FuelCell Energy, 67% are in the favor of a “buy,” while 33% recommend a “hold” on the stock.

Farmer Brothers (FARM) reported net sales of $133.4 million for 1Q16, a decline of $2.6 million, or 1.9%, compared to $136 million in 1Q15.

On November 5, 2015, Farmer Brothers (FARM) reported its financial results for 1Q16. The earnings release wasn’t positive for the stock, which fell by 4% and closed at $29.88 on November 6.

Comparing Hurco Companies (HURC) with its peers for earnings in 2Q15, the company maintained a high EPS (earnings per share) of $2.58.

Hurco announced its 2Q15 earnings report with a 5.10% rise in the net income—compared to 1Q15. The company’s net profit margin was 7.89% in 1Q15.